Andrew Tan on Dealing with Cancer and Obesity

Dr. Andrew Tan obtained a PhD in Cell and Molecular Biology at the National University of Singapore. This was followed by postdoctoral positions in National University of Singapore and Centre of for Integrative Genomics, Switzerland. In 2005, He joined the School of Biological Sciences at Nanyang Technological University.

Current research centered on three processes which are of clinical relevance.

Wound repair: Dr Tan's research group study the communications among the different cell types, especially in diabetic conditions. We use various approaches, such as 3D skin organotypic culture, knockdown technology and appropriate animal models to understand the mechanism and to identify novel wound healing targets. New insights will led to a better understanding of skin biology and aid in the development of better treatment and clinical injury management.

Metabolic Syndrome and Cancer Risk: Obesity is a growing medical and social issue in global health by virtue of its association with numerous chronic diseases. Obesity is also implicated in the etiology and progression of cancer. The complex etiology and multiple risk factors for cancer and metabolic syndrome mandate a wide-ranging and flexible overall research strategy for cancer prevention and control, as well as for successful interventions for weight loss and maintenance.

Dr Tan would be speaking on ‘Dealing with Cancer and Obesity’ at BioPharma Asia Convention’s NTU-SBS Symposium at 2.20pm on 20 March 2012.

The following is an abstract of his presentation:

Obesity has tripled over the last two decade.  It is ranks among the biggest cause of premature death in industrialized countries. Obesity hardly occurs in isolation but is most often part of an array of metabolic abnormalities including type 2 diabetes and hypertension. Traditional methods, such as dieting and increasing physical activity, having limited success. Thus, the need is urgent to identify novel targets and complementary strategies for disease prevention and therapy. I will highlight the identification of potential targets and strategies.

Cancer cells acquire several essential hallmarks that have emerged as potential therapeutic targets. Metastasis is the spread of malignant cells to distant organs and is frequently the most fatal event in tumor progression. Metastasis is largely responsible for the majority of cancer deaths as the metastatic cancer cells are found to be highly aggressive and resistant to anti-tumor drugs. Our study showed that anticancer strategies that focus on redox-based apoptosis induction in tumors are clinically viable. One such strategies involves the invention relates to antagonist of angiopoietin-like ANGPTL4 and methods for the treatment of cancer and proliferative disorders.

Join us at NTU's SBS Symposium! 8 professors will be coming together to share their latest developments in the biopharmaceutical arena at this symposium co-located at BioPharma Asia Convention. Pre-register to attend BioPharma Asia Convention today!

Leave a Reply

Your email address will not be published. Required fields are marked *